rhulL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo

Johnson, Barbara J. B.; Bekker, Linda‐Gail; Rickman, R; Brown, Sheldon T.; Lesser, Marvin; Ress, Stanley; Willcox, Paul A.; Steyn, Lafras M.; Kaplan, Gilla

doi:10.1016/s0962-8479(97)90026-5

Cited by 79 publications

(74 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All these data support the idea that Th1 cells have a predominant role in the immune response to active tuberculosis. On the basis of these results, the use of IL-2 in tuberculosis therapy was suggested, and studies giving both favorable and unfavorable results followed; it was noted that IL-2 may be a potential immunotherapy agent (Johnson et al 1995(Johnson et al , 1997(Johnson et al , 2003. In our study, serum IL-2 levels were also found to be higher in cases with active pulmonary tuberculosis than in cases of inactive tuberculosis or healthy controls.…”

Section: Röllinghoff 2001) It Is Well Known That Cd4+supporting

confidence: 61%

Serum Interleukin-2 and Neopterin Levels as Useful Markers for Treatment of Active Pulmonary Tuberculosis

Turgut

Akbulut

Deveci

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Section: Röllinghoff 2001) It Is Well Known That Cd4+supporting

confidence: 61%

Serum Interleukin-2 and Neopterin Levels as Useful Markers for Treatment of Active Pulmonary Tuberculosis

Turgut

Akbulut

Deveci

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

“…The promise of immunotherapy, an approach that may have important implications for drug-resistant disease (31,32), has yet to show itself as an important part of the arsenal against TB. Although IFN-g, IL-2, IL-12, and thalidomide have been tried as immune modulators in patients with pulmonary TB, the results of experimental studies and clinical trials have been only moderately encouraging (33)(34)(35)(36)(37).…”

Section: Discussionmentioning

confidence: 99%

α-Galactosylceramide as a Therapeutic Agent for PulmonaryMycobacterium tuberculosisInfection

Sada‐Ovalle¹,

Sköld²,

Tian³

et al. 2010

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Rationale: Invariant natural killer T (iNKT) cells are a unique subset of T cells that recognize lipid antigens presented by CD1d molecules. Recent studies have shown that iNKT cells can protect mice against Mycobacterium tuberculosis (Mtb) infection. We sought to determine whether pharmacological activation of iNKT cells by a-galactosylceramide (a-GalCer) could be used to treat tuberculosis (TB). Objectives: We hypothesized that a-GalCer, either alone or in combination with isoniazid, could be used to treat pulmonary TB. Methods: The ability of a-GalCer-activated iNKT cells to suppress Mtb replication was evaluated using an in vitro coculture system. To test its potency in vivo, mice infected with virulent Mtb were treated with a-GalCer alone or in combination with isoniazid. Measurements and Main Results: Quantitative colony-forming unit counts were compared for both experimental systems. Our results show that a-GalCer plus isoniazid controls bacterial growth better than a-GalCer or INH alone, and single or multiple a-GalCer administrations prolong the survival of the mice infected via the aerosol route.Conclusions: Our results demonstrate that a-GalCer administration can improve the outcome of Mtb infection, even when transmitted by the aerosol route. However, a combination of isoniazid and a-GalCer treatment has a synergistic effect on infection control. We conclude that more efficient treatment of TB will be achieved through a combination of classic chemotherapy and modulation of the host immune response.

show abstract

“…After pulmonary administration, complete sterilization in lung was observed only after administration of five doses at every 10 th day whereas to generate same effect orally 46 daily doses were required agglutinin surface modified nanoparticles required only three doses administered each after 14 days for 45 days. Passive targeting of chemotherapeutic compounds to alveolar macrophages has also been explored using pulmonary administration of nanoparticles for the treatment of tuberculosis infections [66][67][68]. Flexibility of the nanoparticle-based formulations was further demonstrated by effective subcutaneous treatment of mice infected with M. tuberculosis [69].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

rhulL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimens and placebo

Cited by 79 publications

References 8 publications

Serum Interleukin-2 and Neopterin Levels as Useful Markers for Treatment of Active Pulmonary Tuberculosis

Serum Interleukin-2 and Neopterin Levels as Useful Markers for Treatment of Active Pulmonary Tuberculosis

α-Galactosylceramide as a Therapeutic Agent for PulmonaryMycobacterium tuberculosisInfection

Present status of nanoparticle research for treatment of Tuberculosis

Contact Info

Product

Resources

About